Is Scheduled Intravenous XXXX Effective in the Pain Management Protocol of @entity173 ?

@entity1 @entity174 @entity4784 @entity173 @entity158 @entity1443 @entity130
BACKGROUND: @entity173 have significant effects on the geriatric population and the health care system. Prior studies have demonstrated both the safety of intravenous (IV) @entity1443 and its efficacy in decreasing perioperative @entity4784 consumption. The purpose of this study is to evaluate the effect of scheduled IV @entity1443 for perioperative @entity158 control on length of hospital stay, @entity158 level, @entity4784 use, rate of missed physical therapy (PT) sessions, adverse effects, and discharge disposition in geriatric @entity1 with @entity173 . METHODS: A retrospective review was performed of all @entity1 65 years and older admitted to a level I @entity130 center, who received operative treatment for a @entity173 over a 2-year period. Demographic data, in-hospital variables, and outcome measures were analyzed. Three hundred thirty-six consecutive @entity174 in 332 @entity1 met inclusion criteria. These @entity1 were divided into 2 cohorts. Group 1 (169 @entity174 ) consisted of @entity1 treated before the initiation of a standardized IV @entity1443 perioperative @entity158 control protocol, and group 2 (167 @entity174 ) consisted of those treated after the protocol was initiated. RESULTS: Group 2 had a statistically significant shorter mean length of hospital stay (4.4 vs 3.8 days), lower mean @entity158 score (4.2 vs 2.8), lower mean @entity4784 usage (41.3 vs 28.3 mg), lower rate of PT sessions missed (21.8% vs 10.4%), and higher likelihood of discharge home (7% vs 19%; P  <= .001). Use of IV @entity1443 was also consistently and independently predictive of the same variables (P < .01). CONCLUSION: The utilization of scheduled IV @entity1443 as part of a standardized @entity158 management protocol for geriatric @entity173 resulted in shortened length of hospital stay, @entity158 levels and @entity4784 use, fewer missed PT sessions, and higher rate of discharge to home. LEVEL OF EVIDENCE: Therapeutic level III.
